CVRx (CVRX) Stock Forecast & Price Target

Compare

197 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CVRX Analyst Ratings

Strong Buy

5 Buy

0 Hold

0 Sell

Based on 5 analysts giving stock ratings to

CVRx

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CVRX Stock 12 Month Forecast

Average Price Target

$12.67

▲(73.32% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for CVRx in the last 3 months. The average price target is $12.67 with a high forecast of $14.00 and a low forecast of $11.00. The average price target represents a 73.32% change from the last price of $7.31.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","16":"$16","7.75":"$7.75","10.5":"$10.5","13.25":"$13.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,7.75,10.5,13.25,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.1,7.63076923076923,8.161538461538461,8.692307692307692,9.223076923076922,9.753846153846153,10.284615384615385,10.815384615384616,11.346153846153847,11.876923076923077,12.407692307692308,12.938461538461539,13.46923076923077,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.1,7.5284615384615385,7.9569230769230765,8.385384615384615,8.813846153846153,9.242307692307692,9.670769230769231,10.099230769230768,10.527692307692307,10.956153846153846,11.384615384615385,11.813076923076924,12.241538461538461,{"y":12.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.1,7.3999999999999995,7.699999999999999,8,8.3,8.6,8.9,9.2,9.5,9.8,10.1,10.4,10.7,{"y":11,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.67,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.98,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.96,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.53,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.29,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.48,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.04,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.56,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.73,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.96,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.19,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.4,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.1,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 46, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$14.00

Average Price Target$12.67

Lowest Price Target$11.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Chase Knickerbocker

Craig-Hallum

Buy

―

Reiterated

01/23/26

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT), Maravai Lifesciences Holdings (NASDAQ: MRVI) and CVRx (NASDAQ: CVRX)

Brandon Vazquez

William Blair

Buy

―

Reiterated

01/23/26

Analysts Are Bullish on These Healthcare Stocks: CVRx (CVRX), Aligos Therapeutics (ALGS)

Frank Takkinen

Lake Street

$14

Buy

91.52%

Upside

Reiterated

01/23/26

CVRx (CVRX) Gets a Buy from Lake Street

William Plovanic

Canaccord Genuity

$11

Buy

50.48%

Upside

Reiterated

01/22/26

Canaccord Genuity Sticks to Their Buy Rating for CVRx (CVRX)

Ross Osborn

Cantor Fitzgerald

$11→$13

Buy

77.84%

Upside

Reiterated

11/06/25

CVRx price target raised to $13 from $11 at Cantor FitzgeraldCVRx price target raised to $13 from $11 at Cantor Fitzgerald

Robbie Marcus

J.P. Morgan

Sell

-4.24%

Downside

Downgraded

05/09/25

CVRx Faces Downgrade: Sales Miss and Reorganization Challenges Lead to Sell Rating

Matthew O'Brien

Piper Sandler

$20→$12

Buy

64.16%

Upside

Reiterated

05/09/25

CVRx price target lowered to $12 from $20 at Piper SandlerCVRx price target lowered to $12 from $20 at Piper Sandler

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Chase Knickerbocker

Craig-Hallum

Buy

―

Reiterated

01/23/26

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT), Maravai Lifesciences Holdings (NASDAQ: MRVI) and CVRx (NASDAQ: CVRX)

Brandon Vazquez

William Blair

Buy

―

Reiterated

01/23/26

Analysts Are Bullish on These Healthcare Stocks: CVRx (CVRX), Aligos Therapeutics (ALGS)

Frank Takkinen

Lake Street

$14

Buy

91.52%

Upside

Reiterated

01/23/26

CVRx (CVRX) Gets a Buy from Lake Street

William Plovanic

Canaccord Genuity

$11

Buy

50.48%

Upside

Reiterated

01/22/26

Canaccord Genuity Sticks to Their Buy Rating for CVRx (CVRX)

Ross Osborn

Cantor Fitzgerald

$11→$13

Buy

77.84%

Upside

Reiterated

11/06/25

CVRx price target raised to $13 from $11 at Cantor FitzgeraldCVRx price target raised to $13 from $11 at Cantor Fitzgerald

Robbie Marcus

J.P. Morgan

Sell

-4.24%

Downside

Downgraded

05/09/25

CVRx Faces Downgrade: Sales Miss and Reorganization Challenges Lead to Sell Rating

Matthew O'Brien

Piper Sandler

$20→$12

Buy

64.16%

Upside

Reiterated

05/09/25

CVRx price target lowered to $12 from $20 at Piper SandlerCVRx price target lowered to $12 from $20 at Piper Sandler

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering CVRx

3 Months

xxx

Success Rate

11/20 ratings generated profit

Average Return

+10.84%

reiterated a xxx

rating 9 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 55.00% of your transactions generating a profit, with an average return of +10.84% per trade.

1 Year

Matthew O'BrienPiper Sandler

Success Rate

11/20 ratings generated profit

Average Return

+16.11%

reiterated a buy rating 9 months ago

Copying Matthew O'Brien's trades and holding each position for 1 Year would result in 55.00% of your transactions generating a profit, with an average return of +16.11% per trade.

2 Years

xxx

Success Rate

7/20 ratings generated profit

Average Return

+1.26%

reiterated a xxx

rating 9 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 35.00% of your transactions generating a profit, with an average return of +1.26% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CVRX Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CVRX has received 18 Buy Ratings, 46 Hold Ratings, and 0 Sell Ratings. CVRX average Analyst price target in the past 3 months is 12.67.

Each month's total comprises the sum of three months' worth of ratings.

CVRX Financial Forecast

CVRX Earnings Forecast

Currently, no earnings data available.

CVRX Sales Forecast

Currently, no sales data available.

CVRX Stock Forecast FAQ

What is CVRX’s average 12-month price target, according to analysts?

Based on analyst ratings, CVRx’s 12-month average price target is 12.67.

What is CVRX’s upside potential, based on the analysts’ average price target?

CVRx has 73.32% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CVRX a Buy, Sell or Hold?

CVRx has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.

What is CVRx’s price target?

The average price target for CVRx is 12.67. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $14.00 ,the lowest forecast is $11.00. The average price target represents 73.32% Increase from the current price of $7.31.

What do analysts say about CVRx?

CVRx’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of CVRX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

CVRx (CVRX) Stock Forecast & Price Target

CVRX Analyst Ratings

CVRX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering CVRx

CVRX Analyst Recommendation Trends

CVRX Financial Forecast

CVRX Earnings Forecast

CVRX Sales Forecast

CVRX Stock Forecast FAQ

Detailed List of Analyst Forecasts